LONFUTRI

Owner

Goods & Services

Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for use as a gene editing therapy; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations for use as a one-time treatment for hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (Type 1 or Type 2); Pharmaceutical and biological preparations for use as a gene editing therapy that inactivates the KLKB1 gene and lowers plasma prekallikrein levels; Pharmaceutical and biological preparations for use as a gene editing therapy for hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for treating and managing swelling attacks; Therapeutic agents in the nature of a CRISPR/Cas9 system for treating hereditary angioedema (HAE)